Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?

Verger, E.; Salamero, Manel; Conill, Carlos

doi:10.1016/0959-8049(92)90510-9

Cited by 136 publications

(82 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It includes variables related to tumor stage, liver functional status, physical status and cancer related symptoms. [189][190][191] The main advantage of the BCLC staging system is that it links staging with treatment modalities and with an estimation of life expectancy that is based on published response rates to the various treatments. It identifies those with early HCC who may benefit from curative therapies, those at intermediate or advanced disease stage who may benefit from palliative treatments, as well as those at end-stage with a very poor life expectancy ( Fig.…”

Section: Staging Systemsmentioning

confidence: 99%

“…Patients who present with a more advanced stage because of liver failure or tumor growth with vascular involvement/extrahepatic spread or physical impairment reflected by a markedly impaired performance status (Ͻ2) [189][190][191] will not benefit from any treatment option, even one with known efficacy in earlier disease. Accordingly, the optimal policy for these subjects is to attempt to enroll them in research studies testing new agents either within phase 2 investigations or within RCT.…”

Section: Treatment Algorithmmentioning

confidence: 99%

See 1 more Smart Citation

Management of hepatocellular carcinoma

2005

View full text Add to dashboard Cite

Section: Staging Systemsmentioning

confidence: 99%

Section: Treatment Algorithmmentioning

confidence: 99%

Management of hepatocellular carcinoma

2005

View full text Add to dashboard Cite

“…In the U.S. studies, patients rated their functional status using the KPS scale that ranged from 30 (I feel severely disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms). Based on the recommendations of Verger et al, 20 the KPS scores were converted to ECOG scores for use in subsequent analyses.…”

Section: Instrumentsmentioning

confidence: 99%

Differences in Composition of Symptom Clusters Between Older and Younger Oncology Patients

Yates

Miaskowski

Cataldo

et al. 2015

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

“…66,67 The former study used a non-HCT-specific comorbidity index, and both studies transformed some Eastern Cooperative Oncology Group scores to KPS percentages, which was previously suggested to be associated with a high level of error. 68 KPS was originally designed to measure self-care, daily activities, and evidence of disease, rendering it both a patient-specific and a disease-specific risk factor. Even though it was shown that impaired performance status is linked to increasing NRM, multiple other studies have failed to show any prediction of NRM by performance status.…”

Section: Are Comorbidities and Performance Status Replaceable?mentioning

confidence: 99%

Comorbidities and Hematopoietic Cell Transplantation Outcomes

Sorror

2010

Hematology

View full text Add to dashboard Cite

Conventional allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option for various hematological diseases due, in part to high-dose conditioning and, in part, to graft-versus-tumor effects. Reduced-intensity or non-myeloablative conditioning regimens have relied mostly on graft-versus-tumor effects for disease control, and their advent has allowed relatively older and medically infirm patients to be offered allo-HCT. However, both HCT modalities have been associated with organ toxicities and graft-versus-host disease, resulting in substantial non-relapse mortality. It has become increasingly important to optimize pre-transplant risk assessment in order to improve HCT decision making and clinical trial assignments. Single-organ comorbidity involving liver, lung, heart, or kidney before HCT has been traditionally found to cause organ toxicity after HCT. Recent efforts have resulted in the advent of a weighted scoring system that could sensitively capture multiple-organ comorbidities prior to HCT. The HCT-comorbidity index (HCT-CI) has provided better prediction of HCT-related morbidity and mortality than other non-HCT-specific indices. Subsequent studies, with the exception of a few studies with modest numbers of patients, have confirmed the prognostic importance of the HCT-CI. Further, the HCT-CI has been consolidated with various disease-specific and patient-specific risk factors to refine assignments of patients to the appropriate HCT setting. Ongoing studies are addressing prospective validation of the HCT-CI, furthering our understanding of biological aging, and enhancing the applicability of the HCT-CI comorbidity coding. Future knowledge of the impacts of multiple comorbidities on post-HCT toxicities might guide new prophylactic and therapeutic interventions to lessen the procedure's mortality.

show abstract

Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?

Cited by 136 publications

References 5 publications

Management of hepatocellular carcinoma

Management of hepatocellular carcinoma

Differences in Composition of Symptom Clusters Between Older and Younger Oncology Patients

Comorbidities and Hematopoietic Cell Transplantation Outcomes

Contact Info

Product

Resources

About